Clinical Trial Update: A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine [Phase 3]

View source ↗

Summary

Phase 3 trial comparing etirinotecan pegol (NKTR-102) to physician's choice in metastatic breast cancer with stable brain metastases; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Etirinotecan Pegol (etirinotecan pegol)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Metastasis, Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-08-27